A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PULSE BIOSCIENCES, INC.
PLSE
$2.0B
Mkt Cap
$30.23
-2.48%
PULSE BIOSCIENCES, INC. (PLSE) has a 5-year average return on invested capital (ROIC) of -86.1%. This is below average and may indicate limited pricing power.
PULSE BIOSCIENCES, INC. (PLSE) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
PULSE BIOSCIENCES, INC. (PLSE) does not currently pay a regular dividend.
PULSE BIOSCIENCES, INC. (PLSE) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
PULSE BIOSCIENCES, INC. (PLSE) generated $-54 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PULSE BIOSCIENCES, INC. (PLSE) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
PULSE BIOSCIENCES, INC. (PLSE) reported earnings per share (EPS) of $-1.08 in its most recent fiscal year.
We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. We developed our proprietary nPulse System (formerly known as CellFX), a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of the skin. In parallel, we have designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and otolaryngology.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | - | - |
| Net Income | -73M | -73M | -54M | -42M | -59M | -64M |
| EPS | $-1.08 | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 |
| Free Cash Flow | -54M | -54M | -36M | -33M | -47M | -55M |
| ROIC | -64.3% | -74.4% | -67.3% | -78.8% | -118.3% | -91.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.17 | 0.00 | 0.00 | -33.79 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -77M | -77M | -56M | -44M | -58M | -63M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -90.2% | -74.4% | -67.3% | -200.5% | -349.9% | -217.3% |
| Shares Outstanding | 67M | 67M | 58M | 50M | 34M | 28M |
| Metric | 2015 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 0 | N/A | N/A | 0 | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 2.2M | 5.5M | 9.6M | 17M | 25M | 26M | 29M | 21M | 28M | 32M | 45M | 45M |
| SG&A | 1.6M | 3.4M | 16M | 20M | 17M | 16M | 19M | 14M | 16M | 24M | 32M | 32M |
| EBIT | -4.5M | -9.5M | -26M | -38M | -48M | -50M | -63M | -58M | -44M | -56M | -77M | -77M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -2.8M | -9.5M | -26M | -38M | -47M | -50M | -64M | -59M | -42M | -54M | -73M | -73M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | -28K | 0 | -119K | 0 | -185K | -13K | -6K | 0 | 0 |
| Returns on Capital | ||||||||||||
| ROIC | -31.2% | -36.2% | -71.7% | -66.8% | -96.8% | -185.9% | -91.8% | -118.3% | -78.8% | -67.3% | -74.4% | -64.3% |
| ROE | N/A | N/A | -71.7% | -66.8% | -96.8% | -185.9% | -217.3% | -349.9% | -200.5% | -67.3% | -74.4% | -90.2% |
| ROA | -19.6% | -46.8% | -67.2% | -62.3% | -83.5% | -119.8% | -133.3% | -88.6% | -61.6% | -55.9% | -64.1% | -77.0% |
| Cash Flow | ||||||||||||
| Op. Cash Flow | -3.3M | -8.1M | -11M | -24M | -34M | -35M | -54M | -47M | -33M | -36M | -54M | -54M |
| Free Cash Flow | -3.4M | -8.1M | -14M | -24M | -35M | -36M | -55M | -47M | -33M | -36M | -54M | -54M |
| Owner Earnings | -3.8M | -9.1M | -22M | -37M | -47M | -47M | -70M | -54M | -41M | -51M | -77M | -77M |
| CapEx | 86K | 64K | 2.6M | 276K | 608K | 441K | 437K | 401K | 121K | 125K | 315K | 315K |
| Maint. CapEx | 57K | 145K | 481K | 992K | 1.2M | 1.1M | 1.1M | 1.4M | 1.2M | 1.2M | 1.1M | 1.1M |
| Growth CapEx | 29K | 0 | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 57K | 145K | 481K | 992K | 1.2M | 1.1M | 1.1M | 1.4M | 1.2M | 1.2M | 1.1M | 1.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 402K | 870K | 11M | 12M | 11M | 10M | 15M | 5.2M | 7.2M | 14M | 21M | 21M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 1.5M | 437K | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -20M | -56M | 15M | -44M | -118M | N/A | -81M |
| Cash & Equiv. | 3.6M | 2.1M | 3.4M | 51M | 6.9M | 12M | 29M | 61M | 44M | 118M | 81M | 81M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 0 | 436K | 65M | 0 | 0 | N/A | N/A |
| Debt/Equity | N/A | N/A | 0.08 | 0.06 | 0.36 | 0.00 | 0.02 | -33.79 | 0.00 | 0.00 | 0.17 | 0.00 |
| Interest Coverage | N/A | -140.0 | -103.5 | -89.8 | -48.8 | -438.3 | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | N/A | 46M | 66M | 31M | 23M | 36M | -2.2M | 44M | 115M | 81M | 81M |
| Total Assets | 14M | 26M | 50M | 71M | 42M | 41M | 54M | 78M | 59M | 132M | 95M | 95M |
| Total Liabilities | N/A | N/A | 3.8M | 4.3M | 11M | 18M | 19M | 80M | 15M | 18M | 14M | 14M |
| Intangibles | 10.0M | 6.5M | 5.9M | 5.2M | 4.5M | 3.9M | 3.2M | 2.6M | 1.9M | 1.2M | 575K | 575K |
| Retained Earnings | -3.1M | -13M | -38M | -76M | -123M | -173M | -236M | -295M | -337M | -391M | -463M | -463M |
| Working Capital | 3.3M | 16M | 36M | 57M | 22M | 15M | 28M | 56M | 39M | 109M | 75M | 75M |
| Current Assets | 4.0M | 17M | 38M | 60M | 26M | 22M | 37M | 62M | 45M | 119M | 83M | 83M |
| Current Liabilities | 660K | 1.0M | 2.2M | 3.1M | 4.5M | 7.6M | 8.5M | 6.0M | 6.7M | 10M | 7.9M | 7.9M |
| Per Share Data | ||||||||||||
| EPS | -0.37 | -0.86 | -1.73 | -2.20 | -2.26 | -2.14 | -2.28 | -1.72 | -0.85 | -0.92 | -1.08 | -1.08 |
| Owner EPS | -0.50 | -0.82 | -1.52 | -2.18 | -2.24 | -2.00 | -2.50 | -1.57 | -0.83 | -0.88 | -1.14 | -1.14 |
| Book Value | N/A | N/A | 3.11 | 3.89 | 1.48 | 0.98 | 1.28 | -0.07 | 0.89 | 1.97 | 1.20 | 1.20 |
| Cash Flow/Share | -0.44 | -0.73 | -0.75 | -1.40 | -1.64 | -1.52 | -1.94 | -1.38 | -0.67 | -0.62 | -0.80 | -1.06 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 7.6M | 11.1M | 14.8M | 17.1M | 20.8M | 23.3M | 27.9M | 34.0M | 49.7M | 58.2M | 67.4M | 67.4M |
| Valuation | ||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -28.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 7.8 | 2.9 | 9.2 | 22.7 | 11.7 | N/A | 14.1 | 9.1 | 12.0 | 25.3 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -12.0% | -3.8% | -12.4% | -12.3% | -6.9% | -13.1% | -57.6% | -5.3% | -3.5% | -5.6% | -2.7% |
| Market Cap | N/A | 68M | 357M | 194M | 284M | 519M | 417M | 82M | 626M | 1.0B | 970M | 2.0B |
| Avg. Price | N/A | 5.24 | 21.69 | 15.61 | 14.11 | 11.40 | 22.62 | 3.80 | 5.58 | 13.35 | 16.67 | 30.23 |
| Year-End Price | N/A | 6.10 | 24.16 | 11.39 | 13.66 | 22.28 | 14.92 | 2.42 | 12.60 | 18.02 | 14.40 | 30.23 |
PULSE BIOSCIENCES, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PULSE BIOSCIENCES, INC. (PLSE) has a return on equity (ROE) of -74.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for PULSE BIOSCIENCES, INC. (PLSE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PULSE BIOSCIENCES, INC. (PLSE) has a book value per share of $1.20, based on its most recent annual SEC filing.